Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
London, UK – 31 Aug 2015: Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.1 Major bleedings were more pronounced in elderly and low-weight patients and raise concerns about the safety of prescriptions in these patients.
EMBARGO : 31 August 2015 at 14:30 BST
“Coronary artery disease and acute coronary syndromes are the cause of death and disability in many patients,” said Dr Raban Jeger, interventional cardiologist and head of the structural heart disease programme at the University Hospital Basel, Switzerland. “In these patients prasugrel, by inhibition of platelet aggregation, prevents recurrent ischaemic events but also may cause bleedings.”He added: “Although prasugrel is more effective than other drugs, it is only approved for patients with acute coronary syndromes. In patients with stable coronary artery disease, however, until now it was unknown whether prasugrel had a similar safety as in acute coronary syndromes or caused side effects without benefit.”To assess the safety of prasugrel in patients with stable coronary artery disease, the investigators performed a prespecified secondary analysis of the BASKET-PROVE (BAsel Kosten Effektivitäts Trial – PROspective Validation Examination) II trial.BASKET-PROVE II was a European multicentre randomised controlled trial that tested the efficacy and safety of two different drug-eluting stents (DES), a biolimus-eluting stent with a bioresorbable polymer and an everolimus-eluting stent with a durable polymer against a bare metal stent between 2010 and 2014. All 2 291 patients enrolled in the trial were treated with aspirin and prasugrel for 12 months irrespective of the indication, i.e., acute coronary syndrome or stable coronary disease. Patients were followed up for two years for major bleeding, defined as a class ≥3 within the Bleeding Academic Research Consorium (BARC) classification.The main results showed that the bioresorbable polymer DES was noninferior to the durable polymer DES and more effective than the bare metal stent. But there was no evidence for better safety or lower rates of very late stent thrombosis beyond one year.2For this analysis, 845 patients with stable coronary artery disease on prasugrel (new indication) were compared with 1 446 patients with acute coronary syndrome on prasugrel (established indication) and - as a historical control group – 822 patients with stable coronary artery disease on clopidogrel (established indication). For the latter comparison, a precursor trial with similar inclusion and exclusion criteria but a comparison with other stents and a clopidogrel-based dual antiplatelet therapy served as a historical control group (BASKET-PROVE).The investigators found that in patients with stable coronary artery disease, prasugrel had a similar safety profile as in patients with acute coronary syndrome, where prasugrel is an approved indication (Figure 1; p=0.167). However, during the treatment period, there was a trend to more major bleedings on prasugrel, which was pronounced in patients at increased bleeding risk (Figure 2; p=0.021 for the period with dual antiplatelet therapy, i.e., the first 12 months, left, and p=0.968 for the period with aspirin only, right). Dr Jeger said: “Of note, in these high-bleeding-risk patients, defined as patients >75 years of age and <60 kg of body weight, the prescribed dose was reduced from 10 mg to 5 mg. Therefore, there were significantly more major bleedings in elderly and low-weight patients despite a reduced dose.” (Figure 2)Dr Jeger concluded: “These findings have relevant implications for the daily use of prasugrel in patients with stable coronary artery disease, and raise a concern regarding the safety of current label prescriptions in patients at high risk of bleeding.”Figure 1: Overall major bleeding events (BARC 3/5) in patients on prasugrel with acute coronary syndromes (blue curve) and stable coronary artery disease (red curve; p=0.167).
Figure 2: Bleeding risk in patients on prasugrel 5 mg (high risk patients, i.e., >75 years of age and/or <60 kg of weight; yellow curve) vs. 10 mg (pink curve). Landmark analysis for the time on dual antiplatelet therapy (first 12 months; p=0.021) vs. time on aspirin only (second 12 months; p=0.968).
1Dr Jeger will present the abstract ‘Bleeding risk of prasugrel-based dual antiplatelet therapy after stent implantation in stable coronary artery disease’ at 14:30 during:• Clinical Trial Update II – Antiplatelet therapy on Monday 31 August at 14:00 in Hyde Park (The Hub)
2Kaiser C, Galatius S, Jeger R, et al.Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation. 2015;131:74-81.
SOURCES OF FUNDING: This trial has been supported by the Basel Cardiovascular Research Foundation, Basel, Switzerland. Prasugrel was provided free of charge by Daiichy Sankyo and Eli Lilly.
DISCLOSURES: Advisory Board for Biotronik, St. Jude Medical and AstraZeneca. Research Support from B. Braun.
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved